FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

British Journal of Cancer
J SouglakosV Georgoulias

Abstract

To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC). A total of 283 chemotherapy-naïve patients with MCC were enrolled (FOLFIRI arm: n=146; FOLFOXIRI arm: n=137). In the FOLFOXIRI arm, CPT-11 (150 mg m(-2)) was given on d1, L-OHP (65 mg m(-2)) on d2, LV (200 mg m(-2)) on days 2 and 3 and 5-FU (400 mg m(-2) as i.v. bolus and 600 mg m(-2) as 22 h i.v. continuous infusion) on days 2 and 3. In the FOLFIRI arm, CPT-11 (180 mg m(-2)) was given on d1 whereas LV and 5-FU were administered in the same way as in the FOLFOXIRI regimen. Both regimens were administered every 2 weeks. There was no difference in terms of overall survival (median OS: 19.5 and 21.5 months, for FOLFIRI and FOLFOXIRI, respectively; P=0.337), median time to disease progression (FOLFIRI: 6.9 and FOLFOXIRI: 8.4 months; P=0.17), response rates (33.6 and 43% for FOLFIRI and FOLFOXIRI, respectively; P=0.168). Patients treated with FOLFOXIRI had a significantly higher incidence of alopecia (P=0.0001), diarrhoea (P=0.0001) and neurosensory toxicity (P=0.001) c...Continue Reading

References

Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A PoonL K Tschetter
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H KöhneH J Schmoll
Jul 1, 1998·British Journal of Cancer·H Bleiberg
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S WadlerE Vokes
Dec 3, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E RaymondE Cvitkovic
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C H KöhneH Hecker
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J SouglakosV Georgoulias
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfredo FalconePierfranco Conte
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyHans-Joachim Schmoll
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier SastreUNKNOWN Cooperative Group for the Treatment of Digestive Tumors

❮ Previous
Next ❯

Citations

May 31, 2014·World Journal of Gastroenterology : WJG·Özgür AkgülMesut Tez
Oct 10, 2006·Future Oncology·Danish MazharWolfgang Heller
Sep 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Dec 6, 2014·Future Oncology·Alberto Sobrero, Alessandro Pastorino
Nov 26, 2011·World Journal of Surgical Oncology·Nabil Ismaili
May 14, 2009·Therapeutics and Clinical Risk Management·Pasquale ComellaLuca Franco
Aug 25, 2009·World Journal of Gastroenterology : WJG·Muhammad Wasif Saif
Sep 24, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S R ParkN K Kim
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Sobrero, E Bennicelli
Aug 18, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F Petrelli, S Barni
Sep 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollA Cervantes
Jan 17, 2012·Scandinavian Journal of Gastroenterology·Bengt Glimelius, Nina Cavalli-Björkman
Dec 14, 2011·Expert Opinion on Pharmacotherapy·Alexander Stein, Dirk Arnold
Nov 10, 2015·Expert Opinion on Biological Therapy·Enrique Sanz-GarciaJosep Tabernero
Dec 17, 2009·Expert Opinion on Pharmacotherapy·Lorenzo FornaroAlfredo Falcone
Apr 14, 2012·Drug Metabolism Reviews·Jose J G MarinOscar Briz
Dec 2, 2015·Oncology Letters·Ayumu MatsuokaYuichi Ando
Jul 29, 2015·Nature Reviews. Clinical Oncology·Chiara CremoliniFotios Loupakis
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Qi ChenFeng Bi
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Cathy Eng, Nabeel Shalan
Mar 25, 2016·Expert Review of Anticancer Therapy·Timothy J PriceJeremy D Shapiro
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Aug 27, 2016·BioMed Research International·Daniela RodriguesSandra F Martins
Oct 11, 2016·Expert Review of Gastroenterology & Hepatology·Erin B MothPrunella Blinman
Dec 3, 2010·Journal of the National Cancer Institute·Carmen AllegraGreg Yothers
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia A TangLillian L Siu
Oct 22, 2014·American Journal of Clinical Oncology·Hung-Ming ChenHao-Wei Teng

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.